Johnson & Johnson is buying RIPTAC developer Halda Therapeutics for 3.05 billion dollars, expanding its prostate cancer pipeline as large drugmakers step up biotech deals in 2025.
Johnson & Johnson said it will acquire Halda Therapeutics, a privately held cancer drug developer based in New Haven, Connecticut, in a 3.05 billion dollar cash deal announced on November 17 2025.
The transaction adds a new precision oncology platform to J&J’s cancer portfolio and supports growth as autoimmune drug Stelara heads into a period of biosimilar competition.
Halda’s lead candidate, HLD-0915, is an oral small molecule for metastatic castration-resistant prostate cancer in a Phase 1/2 trial that began dosing patients in February 2025. The study is listed on ClinicalTrials.gov as NCT06800313, and Halda confirmed first dosing in a company release.
The drug is part of a new class of agents known as regulated induced proximity targeting chimeras, or RIPTAC therapeutics, which link a tumor protein to a pan-essential survival protein to trigger selective cancer cell death. Halda and academic collaborators describe the mechanism in company materials and peer-reviewed work in Cell Chemical Biology.
On October 24 2025, Halda reported first-in-human data showing encouraging safety and anti-tumor activity for HLD-0915 in heavily pretreated prostate cancer patients.
In August 2025, the U.S. Food and Drug Administration granted HLD-0915 fast track designation for metastatic castration-resistant prostate cancer, according to Halda’s news page, which can allow closer FDA interaction and faster review.
Deal terms and J&J strategy
Under the agreement, J&J will pay 3.05 billion dollars in cash for Halda, subject to regulatory approvals and closing conditions. J&J expects the acquisition to close within the next few months and projects about a 15 cent reduction in adjusted 2026 earnings per share from financing costs and equity awards tied to the deal.
The Connecticut biotech drew interest from several major drugmakers, including Novartis, before J&J emerged as the buyer. This is J&J’s second sizable transaction in 2025 after its 14.6 billion dollar takeover of neuroscience group Intra-Cellular Therapies, which closed earlier this year and added antipsychotic drug Caplyta.
What Halda’s RIPTAC platform adds
Halda develops heterobifunctional small molecules that bring together a tumor-specific protein and a survival protein inside cancer cells. Company descriptions and scientific articles explain that this ternary complex blocks the survival protein in cancer cells while largely sparing healthy tissue.
Beyond HLD-0915, Halda lists preclinical programs for breast, lung and p53-mutant tumors on its pipeline page.
The company has raised more than 200 million dollars to support this work, including a 126 million dollar Series B extension announced in August 2024.
In August 2025, Halda also entered an AI-enabled discovery alliance with VantAI that can deliver more than 1 billion dollars in potential payments to the partner across multiple programs.
Biotech deal flow stays active in 2025
Data from tracker DealForma, show at least 23 pharmaceutical acquisitions between 1 billion and 10 billion dollars so far in 2025, pointing to a busy year for mid-sized biotech transactions.
Analysts link this activity to looming patent expiries on blockbuster medicines and a push by large drugmakers to add new cancer and neuroscience assets, a trend reflected in J&J’s recent deals as well as transactions by several peers.
